logologo

English
  • Svenska
EN
  • SV
  • About the company
    About the company
      • About Annexin Pharmaceuticals
      • Business model and strategy
      • Financial information
      • Organization
        • Management
        • Board members
      • History
  • Development program
    Development program
      • The drug candidate ANXV
      • ANXV in vascular disease
      • Research and development
      • Diseases in focus
        • Cardiovascular disease
        • Retinal Vein Occlusion (RVO)
        • Viral Diseases
      • References
  • Contact
    Contact
      • Office
      • Science
      • Investors & media
      • Subscribe
  • Analyst coverage

Investors & media

Anders Haegerstrand
Anders Haegerstrand
CEO
anders.haegerstrand@annexinpharma.com
+46 70 575 50 37
Henrik Palm
Henrik Palm
Chief Financial Officer
henrik.palm@annexinpharma.com
+46 70 540 40 14
  • Contact
    • Office
    • Science
    • Investors & media
    • Subscribe
About the company
  • About Annexin Pharmaceuticals
  • Business model and strategy
  • Financial information
  • Organization
  • History
Development program
  • The drug candidate ANXV
  • ANXV in vascular disease
  • Research and development
  • Diseases in focus
  • References
Contact
  • Office
  • Science
  • Investors & media
  • Subscribe
Analyst coverage
  • Analyst coverage

Annexin Pharmaceuticals AB (publ), Drottninggatan 65, 111 36 Stockholm, Sweden.

E-mail: info@annexinpharma.com. Registration number: 556960-9539.

  • About cookies
  • About personal data
Back to top

Welcome to the Annexin Pharmaceuticals AB website. In order to optimize your use of our website, we use cookies. A cookie is a text file that is stored on your computer. If you would like further information on what a cookie is, what cookies we use, what cookies are for or how to block or delete cookies, please read “About Cookies“. By continuing, you agree to our use of cookies.

Close